| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Although clinical bone morphogentic protein (BMP) therapy is effective, but the required doses are very high. Teriparatide (PTH1-34)is a potent anabolic agent for the treatment of osteoporosis. In the studies, intermittent administration of PTH 1-34 combinedwith BMP transplantation was performed. PTH1-34 administration significantly increased fusion rates and quality of the neuwly formed bone. In addition modeling effect on the excessively induced new bone was observed by the administration of PTH1-34. Bone morphohistometry demonstrated predominat bone formation at endosteum and predominat bone resorption at periosteum. The activation of Wnt signaling and PTH receptor at osteocyte by PTH 1-34 might played a role. Our results suggest that the combined administration BMP and PTH1-34 may enalbe efficinet bone regeneration in the clinical setting.
|
